Full Publications

 

2019

 

15) Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 2019; epub ahead of print.

(ETOP general) (Lung Cancer impact factor 4.486)

 

14) Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer - The ETOP NICOLAS trial. Lung Cancer 2019; 133: 83-87.

(ETOP NICOLAS) (Lung Cancer impact factor 4.486)

 

13) Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasag B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S. Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology 2019; 14 (6): 1086-1094.

(ETOP NICHE) (Journal of Thoracic Oncology impact factor 10.336)

 

12) Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-JM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans A-M, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer 2019; 131: 95-103.

(ETOP Lungscape) (Lung Cancer impact factor 4.486)

 

2018

 

11) Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. Journal of Thoracic Oncology 2018; 13 (12): 1851-1863.

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

10) Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S, European Thoracic Oncology Platform Lungscape Consortium. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology 2018; 13 (3): 413-425.

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

9) Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S, ETOP Lungscape Consortium. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Annals of Oncology 2018; 29 (1): 200-208.

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

2017

 

8) Bubendorf L, Dafni U, Schobel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA, Lungscape Consortium. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 2017; 111: 143-149.

(ETOP Lungscape) (Lung Cancer impact factor 4.486)

 

7) Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massuti B, Palmero R, Aix SP, Carcereny E, Fruh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gomez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine 2017; 5 (5): 435-444.

(ETOP BELIEF) (Lancet Respiratory Medicine impact factor 21.466)

 

6) Peters S, Stahel RA, Dafni U, Ponce Aix S, Massuti B, Gautschi O, Coate L, Lopez Martin A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal O, Palmero Sanchez R, Villa Guzman JC, Collado Martin R, Peralta S, Insa A, Summers Y, Lang I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. Journal of Thoracic Oncology 2017; 12 (4): 752-762.

(ETOP EMPHASIS) (Journal of Thoracic Oncology impact factor 10.336)

 

2014

 

5) Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA, ETOP Lungscape Investigators. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. Journal of Thoracic Oncology 2014; 9 (11): 1675-1684.

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

4) Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernandez-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology 2014; 32 (25): 2780-2787.

(ETOP Lungscape) (Journal of Clinical Oncology impact factor 26.303)

 

3) Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. British Journal of Cancer 2014; 111 (2): 413-420.

(ETOP Lungscape) (British Journal of Cancer impact factor 5.922)

 

2011

 

2) Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011; 74 (3): 544-548.

(ETOP general) (Lung Cancer impact factor 4.486)

 

2010

 

1) Stahel R, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazieres J, Cappuzzo F, Fruh M, Sorensen JB, Blackhall F, Taron M, Gridelli C, O'Byrne K, Rosell R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer 2010; 68 (1): 121-124.

(ETOP general) (Lung Cancer impact factor 4.486)

 

 

Meeting Abstracts

 

2018

 

Curioni A, Stahel RA, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Karachaliou N, Rosell R, Roschitzki-Voser H, Kammler R, Kassapian M, Felip E, Dafni U, Molina M-A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce S. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. Presented at the ESMO Congress 2018 in Munich, Germany. Annals of Oncology 2018; 29 (Suppl 8): viii513. doi: 10.1093/annonc/mdy292.044

(ETOP BELIEF) (Annals of Oncology impact factor 13.926)

 

Peters S, Danson SJ, Hasan B, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Massutí B, Coate L, von Moos R, Zielinski CC, De Maio E, O’Brien M, Roschitzki-Voser H, Dafni U, Stahel RA. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. Presented at the ESMO Congress 2018 in Munich, Germany. Annals of Oncology 2018; 29 (Suppl 8): viii498. doi: 10.1093/annonc/mdy292.008

(ETOP SPLENDOUR) (Annals of Oncology impact factor 13.926)

 

Peters S, De Ruysscher D, Dafni U, Felip E, Guckenberger M, Vansteenkiste JF, Huber R, Nadal E, Irigoyen A, Becker A, Piguet A-C, Kassapian M, Gasca-Ruchti A, Martinez Marti A, Andratschke N, Lambrecht M, Belka C, Roschitzki-Voser H, Stahel RA. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. Presented at the ASCO Annual Meeting 2018 in Chicago, IL, USA. Journal of Clinical Oncology 2018; 36 (Suppl 15): 8510. doi: 10.1200/JCO.2018.36.15 _suppl.8510

(ETOP NICOLAS) (Journal of Clinical Oncology impact factor 26.303)

 

Van Seijen M, Brcic L, Navarro A, Sansano I, Béndek M, Witte B, Brcic I, Kammler R, Stahel RA, Thunnissen E. Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen. Presented at ELCC 2018 in Geneva, Switzerland. Journal of Thoracic Oncology 2018; 13 (4): S11. doi: 10.1016/S1556-0864(18)30301-0

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

2017

 

Thunnissen E, Dafni U, Bubendorf L, Warth A, Biernat W, Pokharel S, Dziadziuszko R, Dienemann H, Cheney R, Marti N, Kassapian M, Finn S, Kerr K, Kammler R, Stahel R, Peters S, ETOP Lungscape. Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort. Presented at the 18th WCLC 2017 in Yokohoma, Japan. Journal of Thoracic Oncology 2017; 12 (11): S1821-S1822. doi: 10.1016/j.jtho.2017.09.494

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn S, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-J, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Polydoropoulou V, Kammler R, Peters S, Stahel RA, ETOP Lungscape. Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ESMO Congress 2017 in Madrid, Spain. Annals of Oncology 2017; 28 (Suppl 5): v573–v594. doi: 10.1093/annonc/ mdx390.002

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Kerr K, Thunnissen E, Dafni U, Soltermann A, Finn S, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-J, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Bille Madsen L, Polydoropoulou V, Kammler R, Peters S, Stahel RA. Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. Journal of Clinical Oncology 2017; 35 (Suppl 15): 8516. doi: 10.1200/JCO.2017.35.15_suppl.8516

(ETOP Lungscape) (Journal of Clinical Oncology impact factor 26.303)

 

Smit EF, Peters S, Dziadziuszko R, Dafni U, Wolf J, Wasąg B, Biernat W, Finn S, Kammler R, Tsourti Z, Rabaglio-Poretti M, Ruepp BU, Roschitzki-Voser H, Stahel RA, Felip E. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. Journal of Clinical Oncology 2017; 35 (Suppl 15): 9070-9070. doi: 10.1200/JCO.2017.35.15_suppl.9070

(ETOP NICHE) (Journal of Clinical Oncology impact factor 26.303)

 

Peters S, Stahel RA, Kassapian M, Guckenberger M, Felip E, De Langen AJ, Huber R, Piguet A-C, Roschitzki-Voser H, De Ruysscher D. A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial. Presented at ELCC 2017 in Geneva, Switzerland. Annals of Oncology 2017; 28 (Suppl 2): 27. doi: 10.1093/annonc/mdx092.009

(ETOP NICOLAS) (Annals of Oncology impact factor 13.926)

 

2016

 

Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel E-J, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernández-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Stahel R, ETOP Lungscape Consortium. Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project. Presented at the 17th WCLC 2016 in Vienna, Austria. Journal of Thoracic Oncology 2017; 12 (11, Suppl 1): S501-S502. doi: 10.1016/j.jtho.2016.11.608

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

De Ruysscher D, Pujol J-L, Popat S, Reck M, Le Pechoux C, Liston A, Speiser D, Coukos G, Kammler R, Dafni U, Tsourti Z, Roschitzki H, Finlayson M, Piguet A-C, Ruepp B, Maibach R, Stahel RA, Peters S. STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. Annals of Oncology 2016; 27 (Suppl 6): vi493–vi496. doi: 10.1093/annonc/mdw389.08

(ETOP STIMULI) (Annals of Oncology impact factor 13.926)

 

Soltermann A, Rulle U, Dafni O, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen Bille  L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn S, Kammler R, Schulze K, Bubendorf L, Stahel RA, Lungscape Consortium. Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. Annals of Oncology 2016; 27 (Suppl 6): vi526–vi544. doi: 10.1093/annonc/mdw392.07

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Rosell R, Karachaliou N, Giménez-Capitán A, Codony-Servat C, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Ponce-Aix S, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Favaretto A, Kammler R, Dafni U, Tsourti Z, Molina-Vila MA, Stahel RA. The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. Presented at the Annual Meeting of the AACR 2016, New Orleans, LA, USA. Cancer Research 2016; 76 (14, Suppl): 269-269. doi: 10.1158/1538-7445.am2016-269

(ETOP BELIEF) (Cancer Research impact factor 9.130)

 

2015

 

Kerr K, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Molina MA, Shames DS, Peters S, Stahel R. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the European Cancer Congress 2015 in Vienna, Austria. European Journal of Cancer 2015; 51 (Suppl 3): S595-S596. doi: 10.1016/S0959-8049(16)31647-1

(ETOP Lungscape) (European Journal of Cancer impact factor 7.191)

 

Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina MA, Rosell R. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Presented at the European Cancer Congress 2015 in Vienna, Austria. European Journal of Cancer 2015; 51 (Suppl 3): S711-S712. doi: 10.1016/S0959-8049(15) 30068-X

(ETOP BELIEF) (European Journal of Cancer impact factor 7.191)

 

Bubendorf L, Dafni U, Finn S, Warth A, Savic S, Thunnissen E, Sejda A, Verbeken E, Tischler V, Marchetti A, Sansano I, Speel E, Cheney R, Nonaka D, Monkhorst K, Di Lorito A, Consuelo Calabuig M, Reidy M, Hager H, Mathieson W, Martorell M, Baas P, Dienemann H, Smit E, Blackhall F, Dingemans A, Felip E, Adjei A, Meldgaard P, Weder W, Vansteenkiste J, Dziadziuszko R, Tsourti Z, Kerr K, Schulze K, Das-Gupta A, Peters S, Stahel R. Prevalence and Clinical Association of MET Gene Amplification in Patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the 16th WCLC 2015 in Denver, CO, USA. Journal of Thoracic Oncology 2015; 10 (9, Suppl 2): S173-S260. doi: 10.1016/S1556-0864(16)30010-7

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Letovanec I, Peters S, Tsourti Z, Finn S, Soltermann A, Bubendorf L, Speel E, Marchetti A, Nonaka D, Hager H, Martorell M, Monkhorst K, Sejda A, Cheney R, Sansano I, Verbeken E, Tischler V, Savic S, Di Lorito A, Consuelo Calabuig M, Felip E, Adjei A, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans A, Dienemann H, Dziadziuszko R, Vansteenkiste J, Kammler R, Dafni U, Kerr K, Thunnissen E, Stahel R. Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project. Presented at the 16th WCLC 2015 in Denver, CO, USA. Journal of Thoracic Oncology 2015; 10 (9, Suppl 2): S407-S760. doi: 10.1016/S1556-0864(16)30012-0

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Peters S, Smit EF, Dafni U, Aix SP, Massuti B, Gautschi O, Coate L, Martín AL, van Heemst R, Berghmans T, Meldgaard P, Dols MC, Noguera JG, Floriani IC, Kassapian M, Kuruvilla YCK, Gasca-Ruchti A, Zielinski C, Gregorc V, Stahel RA, EMPHASIS Collaborative Group. Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. Presented at the ASCO Annual Meeting 2015 in Chicago, IL, USA. Journal of Clinical Oncology 2015; 33 (Suppl 15): 8049-8049. doi: 10.1200/jco.2015.33.15_suppl.8049

(ETOP EMPHASIS) (Journal of Clinical Oncology impact factor 26.303)

 

2014

 

Bubendorf L, Savic S, Dafni O, Tsourti Z, Tischler V, Finn S, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel EJ, Martorell M, Schulze K, Das-Gupta A, Kerr KM, Peters S, Stahel RA. Prevalence and clinical outcomes for patients with MET protein expression in patients with non-small cell lung cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project. Presented at the ESMO Congress 2014 in Madrid, Spain. Annals of Oncology 2014; 25 (Suppl 4): iv418-iv418. doi: 10.1093/annonc/mdu348.5

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

2013

 

Kerr K, Thunnissen E, Blackhall F, Dafni U, Bubendorf L, Hager H, Soltermann A, O'Byrne K, Marchetti A, Dooms C, Sejda A, Sansano I, Nonaka D, Cheney R, De Jong J, Speel E, Jantus-Lewintre E, Zhang Y, Stahel R, Peters S. ALK immunohistochemistry and fluorescence in-situ hybridization in lung adenocarcinomas from the ETOP Lungscape tumour cohort. Presented at the 15th WCLC 2013 in Sydney, Australia. Journal of Thoracic Oncology 2013; 8 (11, Suppl 2): S2-S1348. doi: 10.1097/01.JTO. 0000438438.14562.c8

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Peters S, Weder W, Meldgaard P, O'Byrne K, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit EF, Dingemans A-MC, Savic S, Blackhall FH, Baas P, Jantus-Lewintre E, Kerr KM, Dafni U, Rafael R, Stahel RA, European Thoracic Oncology Platform. The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. Presented at the ASCO Annual Meeting 2013 in Chicago, IL, USA. Journal of Clinical Oncology 2013; 31 (Suppl 15): 7514-7514. doi: 10.1200/jco.2013.31.15_suppl.7514

(ETOP Lungscape) (Journal of Clinical Oncology impact factor 26.303)

 

2012

 

Blackhall F, Peters S, M. Kerr K, O'Byrne K, Hager H, Sejda A, Soltermann A, Dooms C, Felip E, Marchetti A, M. Speel EJ, Price N, Savić S, de Jong J, Martorell M, Thunnissen E, Bubendorf L, Dafni U, Rosell R, Stahel RA. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary results from the European Thoracic Oncology Platform Lungscape project. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix73. doi: 10.1093/annonc/mds391

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Normanno N, Patton S, Blackhall F, Murray S, Kerr K, Dietel M, Filipits M, Benlloch S, Stahel R, Thunnissen E. Results of the second pilot external quality assurance scheme for somatic EGFR mutation testing in non-small cell lung cancer (NSCLC). Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix86.

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Peters S, Dafni U, Bubendorf L, Meldgaard P, O'Byrne K, Wrona A, Weder W, Canela M, Malatesta S, Vansteenkiste J, Dingemans A, Nicolson M, Savic S, Baas P, Peck R, Lu S, Smit E, Jantus-Lewintre E, Rosell R, Stahel R. The European Thoracic Oncology Platform Lungscape project. A way to bridge non-small cell lung cancer molecular characteristics and clinical data. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix385. doi: 10.1093/annonc/mds407

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Stahel R. Lung Cancer: The European Thoracic Oncology Platform. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix58. doi: 10.1093/annonc/mds482

(ETOP general) (Annals of Oncology impact factor 13.926)

 

Thunnissen E, Kerr K, Bubendorf L, Nonaka D, Blackhall F, Kammler R, Speel E, De Jong J, Martorell M, Stahel R. External quality assessment for ALK immunohistochemistry testing in lung adenocarcinoma within the European Thoracic Oncology Platform Lungscape project. Presented at the ESMO Congress 2012 in Vienna, Austria. Annals of Oncology 2012; 23 (Suppl 9): ix80. doi: doi.org/10.1093/ annonc/mds391

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Stahel R, Blackhall F, Peters S, Bubendorf L, Dafni U, Kerr K, Taron M, Thunnissen E, Weder W, Rosell R. The Lungscape project. Presented at ELCC 2012 in Geneva, Switzerland. Journal of Thoracic Oncology 2012; 7 (6, Suppl 1): S13. doi: 10.1097/JTO.0b013e318253d2ff

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Peters S, Blackhall F, Taron M, Rosell R, Hiltbrunner A, Maibach R, King R, Stahel R. ETOP Data system: Combining the comprehensive Lungscape database with a clinical trails platform. Presented at TAT 2012 in Amsterdam, the Netherlands. Annals of Oncology 2012; 23 (Suppl 1): i41. doi: 10.1093/ annonc/mds018

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)

 

Stahel RA, Peters S, Blackhall F, Bubendorf L, Dafni U, Kerr K, Taron M, Thunnissen E, Weder W, Smit E, Rosell R. ETOP activity in the field of biomarkers and predictors. Presented at BTOG 2012 in Dublin, Ireland. Lung Cancer 2012; 77 (Suppl 1): S16-S17. doi: 10.1016/j.lungcan.2012.05.028

(ETOP general) (Lung Cancer impact factor 4.486)

 

2011

 

Blackhall F, Peters S, Kerr K, Kulig K, Bubendorf L, Thunnissen E, Dziadziuszko R, O’Byrne K, Baas P, Weder W, Taron M, Rosell R, Stahel R. ALK Gene Rearrangement: Prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe – A European Thoracic Oncology Group (ETOP) Lungcape Study. Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. Journal of Thoracic Oncology 2011; 6 (6, Suppl 2): S1529-S1530. doi: 10.1097/01.JTO.0000399290.73317.eb

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Peters S, Blackhall F, Boffetta P, Kerr K, Taron M, Bubendorf L, Ciardiello F, Rosell R, Weder W, King R, Stahel R. Building a Comprehensive Database for the Lungscape Project: A Way to Bridge Genomics and Clinical Practice in the European Thoracic Oncology Platform (ETOP). Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. Journal of Thoracic Oncology 2011; 6 (6, Suppl 2): S994-S995. doi: 10.1097/01.JTO.0000399290.73317.eb

(ETOP Lungscape) (Journal of Thoracic Oncology impact factor 10.336)

 

Stahel R, Blackhall F, Peters S, Kerr K, Taron M, Bubendorf L, Weder W, Boffetta P, Ciardiello F, Rosell R. Lungscape - a project of the European Thoracic Oncology Platform (ETOP). Presented at TAT 2011 in Paris, France. Annals of Oncology 2011; 22 (Suppl 3): ii28. doi: 10.1093/annonc/mdr106

(ETOP Lungscape) (Annals of Oncology impact factor 13.926)